Fundraising FoxARCH Venture Partners — 2021 Investments
19 investments dated 2021 · listed companies and verified rows first · show all
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Founder)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsGV (Google Ventures)Newpath PartnersF-Prime CapitalOUP (Osage University Partners)Samsara BioCapitalArrive+1 more
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Zachary D. Hornby(Executive Officer, Director)inRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)Jessica Oien(Chief Legal Officer and Corporate Secretary)in
BoardBenjamin Cravatt, Ph.D.(Director)
Board seatKristina Burow· per SEC Form D
Co-investorsNextech InvestRA CapitalWellington ManagementAlexandriaCity Hill VenturesSectoral Asset Management+3 more
Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering.
AI & Machine LearningBiotechDeep TechSomerville, US
Gevorg Grigoryan(Founder)inMichael Nally(Chief Executive Officer)inAvak Kahvejian(Founder)Geoffrey von Maltzahn(Founder)Molly Gibson(Founder)
Co-investorsFlagship PioneeringAlumni VenturesMarch Capital PartnersNVIDIAAlaska Permanent Fund CorporationALTITUDE LIFE SCIENCE VENTURES+4 more
PerkinElmer is a scientific instrument and technology company that provides analytical tools and services for research, diagnostics, and life sciences applications.
BiotechDeep TechEnterprise SoftwareHealthtechMedical DevicesWaltham, US
Richard Scott PerkinJames M. Mock(Executive Officer)Andrew Okun(Executive Officer)inJoel S. Goldberg(Executive Officer)Tajinder Vohra(Executive Officer)inPrahlad R. Singh(President and Chief Executive Officer)in
Co-investorsAmpersand
Cytrellis develops medical device technologies focused on aesthetic and reconstructive treatments, with expertise spanning dermatology, plastic surgery, and wound healing applications.
BiotechHealthtechMedical DevicesWoburn, US
Rox Anderson, MD(Founder, Medical / Technology Advisor)William G. Austen, Jr. MD(Founder, Medical / Technology Advisor)Doug Levinson, PhD(Founder)Denise Dajles, PhD(President & CEO)John McDonough(Executive Officer, Director)inDavid Stone(Executive Officer)in
Board seatKeith Crandell· per SEC Form D
Co-investorsSands Capital Ventures
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtechStanford, US
Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in
BoardRodger Novak(Chair)in
Co-investors+ND CapitalForbionVenrockFast Track InitiativeLifelinkNextech Invest+3 more
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Board seatKeith Crandell· per SEC Form D
Co-investorsIllumina VenturesOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupJanus Henderson InvestorsRevelation Partners+4 more
RNA therapeutics company with a chip-based mRNA manufacturing platform; acquired by Medici Therapeutics in November 2025.
BiotechEmeryville, US
Igor Khandros(Executive Officer, Director)
Board seatRobert Nelsen· per SEC Form D
Co-investors+ND CapitalBluebird VenturesByers CapitalCraft VenturesFounders FundParadigm+2 more
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
Board seatSteven Gillis· per SEC Form D
Co-investors3B Future Health FundCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersAlexandriaBering Capital+5 more
Xtremity makes the XtremityTT, a thermoformable definitive prosthetic socket system built from an injection-molded, carbon-reinforced polymer preform that clinicians can heat, form, and assemble in about an hour and re-adjust via spot-heating.
HardwareHealthtechMedical DevicesNew MaterialsAspen, US
Mark Joseph(Inventor/Product Designer, company founder)Miguelangel Sosa(Executive Officer, Director)Amy Hill(Executive Officer)Scott Ward(Executive Officer)Maynard Carkhuff(President & CEO)
Board seatRobert Nelsen· per SEC Form D · $15M raise · filed Jun 2021
Co-investorsDecheng CapitalRsquared
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)inBrian Riley(President & Chief Technical Officer)inJoanne Lager(Chief Medical Officer)inWendy DiCicco(Chief Financial Officer)inAdrian Chaisson(Chief of Staff)inJason Cole(Executive Officer)
Co-investorsEaston CapitalRA CapitalSanofi VenturesThink+ Ventures Management, LlcWakestream VenturesForbion+1 more
HiberCell develops therapeutic candidates targeting the Integrated Stress Response pathway to address treatment-resistant cancers, relapse, and metastasis.
BiotechMedical Devices
Julio Aguirre-Ghiso, Ph.D.(Co-Founder)Steven Gillis, Ph.D.(Chairman & Acting CEO)
Co-investorsMagnetic VenturesRaptor Group6 Dimensions CapitalHercules Capital, Inc.Hillhouse Capital
Jaguar Gene Therapy develops gene therapy treatments for severe genetic diseases, focusing on AAV-based platform therapies designed to deliver one-time, long-lasting treatments.
BiotechHealthtechMedical DevicesLake Forest, US
Joseph NolaninJoe Nolan, MBA(Chief Executive Officer)
Co-investorsAIFJDRF T1D FundDeerfield Management CompanyGoldman SachsSamsung Ventures
Lyell Immunopharma is a Nasdaq-listed cell therapy developer engineering T cell therapies for solid tumors and blood cancers.
Co-investorsAxial VCForesite Capital
Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples.
BiotechMedical DevicesCologne, DE
Co-investorsLAVLilly Asia VenturesLake Bleu CapitalMSA CapitalSBCVCSherpa Healthcare Partners+1 more
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Founder)inJeff Bluestone, PhD(Founder and Scientific Advisor; co-founder and former President and CEO)Qizhi Tang, PhD(Founder and Scientific Advisor)Fred Ramsdell, PhD(Founder and Scientific Advisor)Alexander Rudensky, PhD(Founder and Scientific Advisor)Stephen Dilly, MBBS, PhD(President and Chief Executive Officer)
Co-investors8VCFrazier Life SciencesGV (Google Ventures)JDRF T1D FundLAVLifeforce Capital+6 more
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Founder)inAndrew Bellinger(Executive Officer)Kiran Musunuru(Founder)
BoardJohn Evans(Director)Anthony Philippakis(Director)in
Co-investorsF-Prime CapitalGV (Google Ventures)RA CapitalvenBio PartnersWellington ManagementCasdin Capital+3 more
Volastra Therapeutics is a drug discovery and development company working on novel cancer therapies.
BiotechHealthtechNew York, US
Samuel Bakhoum(Co-Founder & Chief Scientific Officer)inLewis Cantley(Founder and Chair of Scientific Advisory Committee)Olivier Elemento(Founder and Scientific Advisor)David P. Southwell(Chief Executive Officer)in
BoardRobert Mittendorff(Director)inJill Goldstein(Director)in
Co-investorsDroia VenturesB Capital GroupB4 CapitalVida VenturesCatalio Capital ManagementPolaris Partners
.jpeg){kind=logo}
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Interline Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.